{"id":"W3044651017","doi":"10.1016/s0140-6736(20)30732-7","title":"Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial","year":2020,"lang":"en","type":"article","venue":"The Lancet","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":491,"is_retracted":false,"has_abstract":false,"ca_institutions":"Université de Montréal; Innovaderm (Canada)","funders":"LEO Pharma; Galderma; Lundbeckfonden; Glenmark Pharmaceuticals; Kiniksa Pharmaceuticals; British Skin Foundation; National Institute for Health and Care Research; Regeneron Pharmaceuticals; Sanofi; Pfizer; Eli Lilly and Company","keywords":"Eczema Area and Severity Index; Medicine; Atopic dermatitis; Placebo; Adverse effect; Randomized controlled trial; Internal medicine; Clinical trial; Janus kinase inhibitor; Clinical endpoint; Severity of illness; Physical therapy; Pediatrics; Dermatology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001301419,0.0001722908,0.000959789,0.00004525068,0.00005997419,0.00001737388,0.0001028088,0.0000745441,0.00002175991],"category_scores_gemma":[0.0001955453,0.0001076537,0.00004688558,0.0001145487,0.0001039374,0.00006094147,0.00004221175,0.0001989962,0.000005665299],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000009509919,"about_ca_system_score_gemma":0.00005344139,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00001467147,"about_ca_topic_score_gemma":0.00002236484,"domain_scores_codex":[0.9988554,0.0001451009,0.0003741377,0.0002343161,0.0001509807,0.0002401328],"domain_scores_gemma":[0.9992427,0.0002008669,0.000116566,0.0002030328,0.00003840847,0.0001984418],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9864388,0.0003174388,0.009517399,0.0004603861,0.0001216581,0.00007986589,0.001711892,0.00005521912,0.0000136853,0.00002057276,0.0006074948,0.0006556152],"study_design_scores_gemma":[0.9835843,0.0003058889,0.01172759,0.0008637272,0.0002119848,0.0000477681,0.0001509457,0.002674842,0.0001356852,0.00001340227,0.0001643326,0.0001195127],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9900196,0.0008137956,0.00007070881,0.004340263,0.00003191003,0.004332687,0.00003292391,0.00002917583,0.0003289663],"genre_scores_gemma":[0.9970586,0.0002765626,0.00009601745,0.002219039,0.0001736531,0.000130053,0.0000163717,0.00001339374,0.00001635842],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.007038982,"threshold_uncertainty_score":0.4389991,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02407745882816653,"score_gpt":0.2923664040459151,"score_spread":0.2682889452177485,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}